Clinical Trial

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2026 (before its estimated July 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if CS060380 tablets works to treat non-alcoholic steatohepatitis(NASH) in adults.It will also learn about the safety of CS060380 tablets.The main questions it aims to answer are: * After 12 weeks of administration, what was the percentage change in fat content evaluated by MRI-PDFF compared to the baseline？ * What medical problems do participants have when taking CS060380 tablets? Researchers will compare CS060380 tablets to a placebo (a look-alike substance that contains no drug) to see if CS060380 tablets works to treat NASH. Participants will: * Take CS060380 tablets or a placebo every day for 12 weeks * Visit the clinic for checkups and tests at the frequency required by the protocol * Keep a diary of their symptoms and the number of tablets taken
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-21; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-10-20
Trial Details
NCT Number NCT07198386
Lead Sponsor Cascade Pharmaceuticals, Inc
Conditions NASH
Enrollment 120 participants
Start Date 2025-09-30
Primary Completion 2026-07-24 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-13